Anita Dushyanth
Stock Analyst
(n/a)
# 4,648
Out of 4,648 analysts
4
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:
Stocks Rated by Anita Dushyanth
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| URGN UroGen Pharma | Initiates: Buy | $20 | $11.93 | +67.64% | 1 | Apr 27, 2022 | |
| SERA Sera Prognostics | Initiates: Buy | $13 | $7.95 | +63.52% | 1 | Apr 27, 2022 | |
| BTAI BioXcel Therapeutics | Initiates: Buy | $75 | $0.64 | +11,529.71% | 1 | Apr 9, 2021 | |
| PCRX Pacira BioSciences | Initiates: Buy | $93 | $16.45 | +465.35% | 1 | Apr 9, 2021 |
UroGen Pharma
Apr 27, 2022
Initiates: Buy
Price Target: $20
Current: $11.93
Upside: +67.64%
Sera Prognostics
Apr 27, 2022
Initiates: Buy
Price Target: $13
Current: $7.95
Upside: +63.52%
BioXcel Therapeutics
Apr 9, 2021
Initiates: Buy
Price Target: $75
Current: $0.64
Upside: +11,529.71%
Pacira BioSciences
Apr 9, 2021
Initiates: Buy
Price Target: $93
Current: $16.45
Upside: +465.35%